{"id":1057744,"date":"2012-12-06T22:41:12","date_gmt":"2012-12-06T22:41:12","guid":{"rendered":"http:\/\/www.longevitymedicine.tv\/emotional-activation-from-theory-to-practice-video\/"},"modified":"2024-08-17T19:35:31","modified_gmt":"2024-08-17T23:35:31","slug":"emotional-activation-from-theory-to-practice-video-2","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/multiple-sclerosis\/emotional-activation-from-theory-to-practice-video-2.php","title":{"rendered":"Emotional Activation from Theory to Practice – Video"},"content":{"rendered":"


Emotional Activation from Theory to Practice
Yves Furet and Daniel Baumgartner, partners at LeadX, introduce the Betaferon case: possibly the clearest piece of evidence that the emotional-activation approach works in the pharmaceutical world. Betaferon is the first ever multiple sclerosis medicine. Some years after launch, sales were stagnating and market share was suffering. The product was then filled with emotions: the paradigm was shifted - attention was placed on patients #39; empowerment. Sales skyrocketed (an increase of 10% achieved in only 6 months). Certainly an interesting case study for all interested in pharma industry management and emotional activation.From:Stefano DavanzoViews:1 0ratingsTime:03:25More inPeople Blogs
<\/p>\n

See the original post:
\nEmotional Activation from Theory to Practice - Video<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Emotional Activation from Theory to Practice Yves Furet and Daniel Baumgartner, partners at LeadX, introduce the Betaferon case: possibly the clearest piece of evidence that the emotional-activation approach works in the pharmaceutical world. Betaferon is the first ever multiple sclerosis medicine. Some years after launch, sales were stagnating and market share was suffering. The product was then filled with emotions: the paradigm was shifted - attention was placed on patients' empowerment. Sales skyrocketed (an increase of 10% achieved in only 6 months). Certainly an interesting case study for all interested in pharma industry management and emotional activation.From:Stefano DavanzoViews:1 0ratingsTime:03:25More inPeople Blogs Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":64,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"limit_modified_date":"","last_modified_date":"","_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[1246866],"tags":[],"class_list":["post-1057744","post","type-post","status-publish","format-standard","hentry","category-multiple-sclerosis"],"modified_by":null,"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/1057744"}],"collection":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/users\/64"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/comments?post=1057744"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/1057744\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/media?parent=1057744"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/categories?post=1057744"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/tags?post=1057744"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}